[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA32614B1 - Compositions therapeutiques contenant du macitentan - Google Patents

Compositions therapeutiques contenant du macitentan

Info

Publication number
MA32614B1
MA32614B1 MA33675A MA33675A MA32614B1 MA 32614 B1 MA32614 B1 MA 32614B1 MA 33675 A MA33675 A MA 33675A MA 33675 A MA33675 A MA 33675A MA 32614 B1 MA32614 B1 MA 32614B1
Authority
MA
Morocco
Prior art keywords
compositions containing
therapeutic compositions
containing macitentan
macitentan
compound
Prior art date
Application number
MA33675A
Other languages
Arabic (ar)
English (en)
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32614(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA32614B1 publication Critical patent/MA32614B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un produit contenant le composé de formule (I) ci-après ou un sel pharmaceutiquement acceptable de ce composé, en combinaison avec au moins un composé présentant des propriétés agonistes du récepteur de la prostacycline (IP) ou un sel pharmaceutiquement acceptable de celui-ci.
MA33675A 2008-08-13 2011-03-07 Compositions therapeutiques contenant du macitentan MA32614B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (fr) 2008-08-13 2009-08-12 Compositions thérapeutiques contenant du macitentan

Publications (1)

Publication Number Publication Date
MA32614B1 true MA32614B1 (fr) 2011-09-01

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33675A MA32614B1 (fr) 2008-08-13 2011-03-07 Compositions therapeutiques contenant du macitentan

Country Status (29)

Country Link
US (3) US8809334B2 (fr)
EP (2) EP2315587B1 (fr)
JP (3) JP5764061B2 (fr)
KR (1) KR101678699B1 (fr)
CN (1) CN102099026B (fr)
AR (1) AR073031A1 (fr)
AU (1) AU2009280843B2 (fr)
BR (1) BRPI0917661B8 (fr)
CA (1) CA2731370C (fr)
CY (2) CY1119826T1 (fr)
DK (2) DK2315587T3 (fr)
ES (2) ES2763176T3 (fr)
HK (1) HK1253355B (fr)
HR (2) HRP20171917T1 (fr)
HU (2) HUE036071T2 (fr)
IL (1) IL211143A0 (fr)
LT (2) LT3300729T (fr)
MA (1) MA32614B1 (fr)
MX (1) MX350011B (fr)
MY (1) MY178894A (fr)
NO (1) NO2315587T3 (fr)
NZ (1) NZ591601A (fr)
PL (2) PL2315587T3 (fr)
PT (2) PT2315587T (fr)
RU (1) RU2519161C2 (fr)
SI (2) SI2315587T1 (fr)
TW (1) TWI446911B (fr)
WO (1) WO2010018549A2 (fr)
ZA (1) ZA201101900B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
MX2010008745A (es) * 2008-02-28 2010-08-30 Nippon Shinyaku Co Ltd Inhibidor de fibrosis.
PT2315587T (pt) 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
EP3554507A1 (fr) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Procédés et compositions de traitement de l'hypertension pulmonaire et d'autres troubles des poumons
SG11202102518VA (en) * 2018-09-14 2021-04-29 Pharmosa Biopharm Inc Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
CA3123990A1 (fr) * 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique pour le traitement de l'hypertension arterielle pulmonaire
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
BRPI0116237B8 (pt) * 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
CN1481244A (zh) * 2000-12-19 2004-03-10 Ĭ��ר���ɷ����޹�˾ 含有吡唑并[4,3-d]嘧啶和抗血栓形成剂、钙拮抗剂、前列腺素或前列腺素衍生物的药物制剂
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (fr) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (fr) 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combinaison de prostacycline ou d'analogues de la prostacycline, et d'antagonistes du recepteur de l'endotheline pour le traitement de l'hypertension arterielle pulmonaire
CN100379730C (zh) 2002-12-02 2008-04-09 埃科特莱茵药品有限公司 嘧啶-磺酰胺及其作为内皮素受体拮抗剂的应用
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
PT1928409E (pt) * 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
WO2009104149A1 (fr) 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combinaison comprenant du paclitaxel destinée au traitement du cancer des ovaires
PT2315587T (pt) 2008-08-13 2018-01-31 Actelion Pharmaceuticals Ltd Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan

Also Published As

Publication number Publication date
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
BRPI0917661A2 (pt) 2015-12-01
PL2315587T3 (pl) 2018-03-30
RU2011109084A (ru) 2012-09-20
PT2315587T (pt) 2018-01-31
ES2763176T3 (es) 2020-05-27
US8809334B2 (en) 2014-08-19
JP5764061B2 (ja) 2015-08-12
SI2315587T1 (en) 2018-04-30
US9597331B2 (en) 2017-03-21
ES2652590T3 (es) 2018-02-05
HRP20171917T1 (hr) 2018-02-09
BRPI0917661B1 (pt) 2019-12-17
JP2015187148A (ja) 2015-10-29
WO2010018549A3 (fr) 2010-07-29
CY1122641T1 (el) 2021-03-12
PL3300729T3 (pl) 2020-04-30
CY1119826T1 (el) 2018-06-27
MX2011001625A (es) 2011-03-29
DK2315587T3 (en) 2018-01-02
TW201010985A (en) 2010-03-16
WO2010018549A2 (fr) 2010-02-18
NZ591601A (en) 2012-12-21
MY178894A (en) 2020-10-21
US20140329824A1 (en) 2014-11-06
CA2731370C (fr) 2017-03-14
US20160022678A1 (en) 2016-01-28
JP5956026B2 (ja) 2016-07-20
HK1253355B (zh) 2020-06-19
HRP20192204T1 (hr) 2020-03-06
JP5956025B2 (ja) 2016-07-20
EP2315587A2 (fr) 2011-05-04
SI3300729T1 (sl) 2020-02-28
AU2009280843A1 (en) 2010-02-18
US20110136818A1 (en) 2011-06-09
AR073031A1 (es) 2010-10-06
KR20110045006A (ko) 2011-05-03
US9173881B2 (en) 2015-11-03
LT3300729T (lt) 2020-01-10
LT2315587T (lt) 2018-01-10
MX350011B (es) 2017-08-22
CN102099026B (zh) 2012-08-29
HK1253355A1 (zh) 2019-06-14
EP3300729A1 (fr) 2018-04-04
JP2015180683A (ja) 2015-10-15
BRPI0917661B8 (pt) 2021-05-25
CA2731370A1 (fr) 2010-02-18
HUE047767T2 (hu) 2020-05-28
IL211143A0 (en) 2011-04-28
HUE036071T2 (hu) 2018-06-28
DK3300729T3 (da) 2020-01-20
TWI446911B (zh) 2014-08-01
CN102099026A (zh) 2011-06-15
ZA201101900B (en) 2012-08-29
EP2315587B1 (fr) 2017-10-25
AU2009280843B2 (en) 2015-03-05
JP2011530581A (ja) 2011-12-22
PT3300729T (pt) 2020-01-20
NO2315587T3 (fr) 2018-03-24
EP3300729B1 (fr) 2019-10-09

Similar Documents

Publication Publication Date Title
MA32614B1 (fr) Compositions therapeutiques contenant du macitentan
MX2011011156A (es) COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
GEP20115140B (en) Substituted spirocyclic cgrp receptor antagonists
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
WO2004082605A3 (fr) Antagonistes des recepteurs du cgrp spirohydantoine anilides bicycliques
MA42145A (fr) Triazoles agonistes du récepteur apj
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA32901B1 (fr) Composes utiles pour l'inhibition de la chk1
TW200745024A (en) Carboxamide derivatives as muscarinic receptor antagonists
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
EP1861399A4 (fr) Antagonistes du recepteur du cgrp
WO2007096763A3 (fr) Pipéridinoylpyrrolidines en tant qu'agonistes du récepteur de la mélanocortine de type 4
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
GB0510143D0 (en) Novel compounds A1
CY1112500T1 (el) Νεες ετεροκυκλικες ενωσεις ως ανταγωνιστες μglu5
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS